2-nonyl-thiazolidine | 116112-94-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 2-nonyl-thiazolidine
• 英文别名: 2-Nonylthiazolidine；2-nonyl-1,3-thiazolidine
• CAS: 116112-94-8
• 化学式: C₁₂H₂₅NS
• 分子量: 215.403
• InChiKey: DOTWLKBBHRRWHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 2-nonyl-thiazolidine 在 potassium carbonate 作用下， 生成 N(methylcarbonyl)-2-nonyl-1,3-thiazolidine
  参考文献：
  名称：

  Tondeur,R. et al., Bulletin de la Societe Chimique de France, 1964, p. 2493 - 2499

  摘要：

  DOI：

文献信息

• Benzene compounds
  申请人：SUZUKI Nobuyasu

  公开号：US20070105899A1

  公开（公告）日：2007-05-10

  The present invention provides novel benzene compounds presented by the following formulas, and analogs thereof, that exert an ACC activity-inhibiting effect that is effective in the treatment of obesity, hyperlipemia, fatty liver, hyperglycemia, impaired glucose tolerance, diabetes, diabetic complications (diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, and diabetic macroangiopathy, hypertension, arteriosclerosis), hypertension, and arteriosclerosis.

  本发明提供了以下公式所示的新型苯化合物及其类似物，具有ACC活性抑制作用，对肥胖、高脂血症、脂肪肝、高血糖、糖耐量受损、糖尿病、糖尿病并发症（糖尿病周围神经病变、糖尿病肾病、糖尿病视网膜病变和糖尿病大血管病变、高血压、动脉硬化）以及高血压和动脉硬化的治疗有效。
• Benzoxazepine Compound
  申请人：Marui Shogo

  公开号：US20080227770A1

  公开（公告）日：2008-09-18

  A compound represented by the formula [1]: wherein ring A and ring B each represent an optionally substituted benzene ring; ring C represents an optionally further substituted aromatic ring; R 1 represents a lower alkyl group optionally substituted with an optionally substituted hydroxyl group; X 1a represents a bond or optionally substituted lower alkylene; X 1b represents a bond or optionally substituted lower alkylene; x 2 represents a bond, —O— or —S—; X 3 represents a bond or an optionally substituted divalent hydrocarbon group; Y represents an optionally esterified or amidated carboxyl group, or a salt thereof. The compound of the formula [I] is safer and has more potent lipid lowering activity such as squalene synthase inhibitory activity (cholesterol lowering activity) and triglyceride lowering activity, and thus it is a compound useful as an agent for preventing or treating hyperlipemia.

  一种由公式[1]表示的化合物：其中环A和环B分别表示可选择性取代的苯环；环C表示可选择性进一步取代的芳香环；R1表示可选择性取代的较低的烷基，其中还可选择性地取代有一个或多个羟基基团；X1a表示一个键或可选择性取代的较低的烷基烯；X1b表示一个键或可选择性取代的较低的烷基烯；x2表示一个键，-O-或-S-；X3表示一个键或可选择性取代的双价碳氢基团；Y表示可选择性酯化或酰胺化的羧基，或其盐。公式[I]的化合物更安全，并具有更强的降脂活性，如角鲨烷合酶抑制活性（降低胆固醇活性）和三酰甘油降低活性，因此它是一种有用的化合物，可用作预防或治疗高脂血症的药物。
• DRUGS FOR COMPLICATIONS OF DIABETES AND NEUROPATHY AND UTILIZATION THEREOF
  申请人：Ajinomoto Co., Inc.

  公开号：EP1283054A1

  公开（公告）日：2003-02-12

  There are provided a medicament excellent in prevention, improvement, treatment, etc. of a diabetic complication, and a medicament excellent in prevention, improvement, treatment, etc. of a neuropathy, each using a postprandial blood sugar-lowering agent as an effective ingredient therefor. Particularly, D-phenylalanine derivatives such as nateglinide are useful as an oral medicine. According to the present invention, these excellent medicaments, a method for use thereof (a method for administration thereof to a living subject in the above treatment, etc.), and a use of the postprandial blood sugar-lowering agent for production of the said medicaments, and the like are provided. At least one agent selected from an antihypertensive agent, a vasodilating agent and an anti-hyperlipidemic agent may be used at the same time with the postprandial blood sugar-lowering agent, by mixing further such at least one agent selected from an antihypertensive agent, a vasodilating agent and an anti-hyperlipidemic agent in (with) such above medicament or by combining them for concomitant use, whereby the effect for prevention, improvement, treatment, etc. of the diabetic complication described above can be enhanced much more.

  提供了一种在预防、改善和治疗糖尿病并发症等方面效果显著的药物，以及一种在预防、改善和治疗神经病变等方面效果显著的药物，每种药物都使用餐后降血糖剂作为有效成分。特别是D-苯丙氨酸衍生物，如纳格列奈，作为口服药物非常有用。 根据本发明，提供了这些优秀的药物、其使用方法（在上述治疗中对活体给药的方法等）以及用于生产上述药物的餐后降血糖剂的用途等。至少一种选自抗高血压剂、血管扩张剂和抗高血脂剂的药剂可与餐后降血糖药剂同时使用，方法是将至少一种选自抗高血压剂、血管扩张剂和抗高血脂剂的药剂进一步混合在上述药物中（与上述药物一起），或将它们结合起来同时使用，从而达到预防、改善、治疗等上述糖尿病并发症的效果。因此，上述糖尿病并发症的预防、改善、治疗等效果可大大增强。
• MEDICINAL COMPOSITION FOR INHIBITING THE EXPRESSION OF ATP-CITRATE LYASE AND USE THEREOF
  申请人：Ajinomoto Co., Inc.

  公开号：EP1547614A1

  公开（公告）日：2005-06-29

  The present invention provides a pharmaceutical composition for suppression of the expression of ATP citrate lyase, which contains a compound that suppresses the expression of ATP citrate lyase by the in vivo administration. The compounds suppress the expression of ATP citrate lyase by the in vivo administration include insulin secretagogues such as nateglinide. This pharmaceutical composition is effective in preventing, improving and treating metabolic syndrome, in particular, liver disorders related to abnormal lipid metabolism such as fatty liver and NASH.

  本发明提供了一种抑制ATP柠檬酸酶表达的药物组合物，其中含有一种通过体内给药抑制ATP柠檬酸酶表达的化合物。通过体内给药抑制 ATP 枸橼酸酶表达的化合物包括胰岛素促泌剂，如纳格列奈。该药物组合物可有效预防、改善和治疗代谢综合征，特别是与脂肪代谢异常有关的肝脏疾病，如脂肪肝和非酒精性肝病。
• BENZOXAZEPINE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1650201A1

  公开（公告）日：2006-04-26

  A compound represented by the formula [1]: wherein ring A and ring B each represent an optionally substituted benzene ring; ring C represents an optionally further substituted aromatic ring; R1 represents a lower alkyl group optionally substituted with an optionally substituted hydroxyl group; X1a represents a bond or optionally substituted lower alkylene; X1b represents a bond or optionally substituted lower alkylene; X2 represents a bond, -O- or -S-; X3 represents a bond or an optionally substituted divalent hydrocarbon group; Y represents an optionally esterified or amidated carboxyl group, or a salt thereof. The compound of the formula [I] is safer and has more potent lipid lowering activity such as squalene synthase inhibitory activity (cholesterol lowering activity) and triglyceride lowering activity, and thus it is a compound useful as an agent for preventing or treating hyperlipemia.

  由式 [1] 表示的化合物： 其中，环 A 和环 B 各代表一个任选取代的苯环；环 C 代表一个任选进一步取代的芳环；R1 代表一个任选被羟基取代的低级烷基；X1a 代表一个键或任选取代的低级亚烷基；X1b 代表一个键或任选取代的低级亚烷基；X2 代表一个键、-O- 或-S-；X3 代表一个键或任选取代的二价烃基；Y 代表一个任选酯化或酰胺化的羧基或其盐。式[I]化合物更安全，具有更强的降脂活性，如角鲨烯合成酶抑制活性（降胆固醇活性）和降甘油三酯活性，因此它是一种可用于预防或治疗高脂血症的化合物。